MLTX
MoonLake Immunotherapeutics
11.40$
-0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -62,540.9% | -75,732.1% | – | – | -47,593.2% | – | – | – | – | – | – | – | |
| – | 16.7% | 1,661.8% | – | – | 1,277.7% | – | – | – | – | – | – | – | |
| – | 8,134.1% | 8,496.3% | – | – | 1,898.4% | – | – | – | – | – | – | – | |
| – | -33,121.1% | -14,413.8% | – | – | -3,829.9% | – | – | – | – | – | – | – | |
| – | 1,442.1% | 1,074.1% | – | – | 172.4% | – | – | – | – | – | – | – | |
| – | 592,089.9% | -145,931.7% | – | – | -144,654.6% | – | – | – | – | – | – | – | |
| – | – | -0.3% | – | – | 0.0% | – | – | – | – | – | – | – | |
| – | 143,968.1% | 258,273.4% | – | – | 148.0% | – | – | – | – | – | – | – | |
| – | 673,845.0% | 36,842.6% | – | – | -191,683.7% | – | – | – | – | – | – | – | |
| – | -63,983.0% | -76,806.2% | – | – | -47,765.6% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.